Is tesamorelin a GHRH or GHRP? Tesamorelin is a GHRH analog, not a GHRP. Learn its structure, FDA-approved uses, and how it differs from GHRPs.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, not a growth hormone-releasing peptide (GHRP). It mimics the body's natural GHRH to stimulate growth hormone release from the pituitary gland. This makes tesamorelin part of the GHRH drug class, while GHRPs like ipamorelin and GHRP-6 act on the ghrelin receptor.
What Is Tesamorelin?
Tesamorelin is a synthetic peptide approved by the FDA under the brand names Egrifta and Egrifta SV. Its international nonproprietary name (INN) is tesamorelin, and it is also supplied as tesamorelin acetate. The phrase tesamorelin o que é is Portuguese for what is tesamorelin, and the answer is the same: it is a GHRH analog used for a specific medical condition.
Tesamorelin is not a general weight-loss drug. It is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy. This is a narrow, FDA-approved use, not a cosmetic or athletic one.
Tesamorelin Structure and Acetate Form
The tesamorelin structure is based on human GHRH(1-44). It contains 44 amino acids and has a trans-3-hexenoyl group attached to the N-terminus. This modification makes the peptide more resistant to breakdown and extends its activity compared with native GHRH.
The pharmaceutical product is a tesamorelin acetate peptide, meaning the active ingredient is formulated as an acetate salt. It is given by subcutaneous injection. The acetate form improves stability and solubility for injection.
GHRH vs. GHRP: Key Differences
GHRH analogs and GHRPs both can raise growth hormone, but they do so through different receptors. GHRH analogs bind the GHRH receptor. GHRPs bind the ghrelin receptor, also called the GHS-R1a receptor.
| Feature | GHRH analogs | GHRPs |
|---|---|---|
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Examples | Tesamorelin, sermorelin, CJC-1295 | Ipamorelin, GHRP-2, GHRP-6, hexarelin |
| FDA approval | Tesamorelin is approved for HIV-associated lipodystrophy | Most GHRPs are not FDA-approved for human use |
| Mechanism | Stimulates GH synthesis and release | Stimulates GH release via ghrelin receptor |
If you are comparing cjc 1295 or tesamorelin, both are GHRH analogs, but only tesamorelin has an FDA-approved indication. This is a major practical difference for researchers and clinicians.
How Tesamorelin Works in the Body
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary. This triggers the release of growth hormone into the bloodstream. Growth hormone then stimulates the liver and other tissues to produce insulin-like growth factor 1 (IGF-1).
Because tesamorelin acts on the GHRH receptor, it is not a GHRP. It does not directly activate the ghrelin receptor. The tesamorelin GHRH classification is based on this receptor specificity.
FDA Approval and Safety
The FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy. A later formulation, Egrifta SV, requires a lower injection volume. Tesamorelin is not approved for weight loss, bodybuilding, or anti-aging in the United States.
Common side effects include injection-site reactions, joint pain, muscle pain, swelling, and numbness or tingling. Tesamorelin can also raise IGF-1 levels, and long-term effects of elevated IGF-1 are still being studied. Anyone considering tesamorelin should consult a healthcare professional.
Related Peptide Classification Questions
People often confuse peptide categories. For example, asking is growth hormone a steroid or peptide clarifies that growth hormone is a peptide hormone, not a steroid. Tesamorelin is also a peptide, not a steroid.
Other questions like what is bpc 157 peptide relate to a different peptide studied for tissue repair, not for GH release. Similarly, when people ask is tirzepatide a glp 1 or 2, they are sorting out drug classes, just as this article sorts out GHRH versus GHRP. And if you wonder is igf-1 lr3 worth it, note that IGF-1 LR3 is downstream of GH action, while tesamorelin acts upstream at the pituitary.
In short, tesamorelin is a GHRH analog. It is not a GHRP. Its structure, receptor target, and FDA approval all support that classification.
Frequently Asked Questions
Is tesamorelin a GHRH or GHRP?
Tesamorelin is a GHRH analog. It binds the GHRH receptor and stimulates growth hormone release from the pituitary. It is not a GHRP, which would act on the ghrelin receptor.
What is tesamorelin used for?
Tesamorelin is FDA-approved for HIV-associated lipodystrophy, specifically to reduce excess abdominal fat in adults with HIV. It is not approved for general weight loss, bodybuilding, or anti-aging. Use outside this indication is off-label and should be discussed with a healthcare professional.
What is the structure of tesamorelin?
Tesamorelin is a 44-amino-acid peptide based on human GHRH(1-44). It has a trans-3-hexenoyl modification at the N-terminus, which improves stability. The drug is formulated as tesamorelin acetate for subcutaneous injection.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.